11 April 2023AmericasStaff writer

BMS and cancer centre settle patent exploitation clash

Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Fed Circ affirms invalidation of two cancer treatment patents

17 August 2023 Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Big Pharma

BMS petitions SCOTUS to revive $1.2bn win

16 June 2022 BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

BMS and cancer centre settle patent exploitation clash

More on this story

Editor's picks

Editor's picks

More features